<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Pulmonary Nodule Management - Skolyn Documentation</title>
<link href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700&family=Google+Sans+Text:wght@400;500&display=swap" rel="stylesheet">
<style>*{margin:0;padding:0;box-sizing:border-box}body{font-family:'Google Sans Text','Google Sans',Roboto,'Helvetica Neue',Arial,sans-serif;max-width:900px;margin:0 auto;padding:48px 40px;color:#1d1d1f;line-height:1.8;font-size:15px}.doc-id-bar{display:flex;justify-content:space-between;align-items:center;padding:12px 20px;background:#f8f9fa;border:1px solid #e8eaed;border-radius:8px;margin-bottom:24px;font-size:13px;color:#5f6368}.doc-id-bar .doc-id{font-family:'Google Sans',sans-serif;font-weight:700;color:#1a73e8;font-size:14px;letter-spacing:.5px}.doc-id-bar .doc-class{padding:4px 12px;background:#e8f0fe;color:#1a73e8;border-radius:100px;font-weight:500;font-size:12px}.doc-header{border-bottom:3px solid #1a73e8;padding-bottom:28px;margin-bottom:40px}.doc-header h1{font-family:'Google Sans',sans-serif;font-size:32px;font-weight:700;margin-bottom:8px}.doc-header .subtitle{font-size:16px;color:#5f6368;margin-bottom:16px}.doc-header .meta-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(200px,1fr));gap:12px;font-size:13px;color:#5f6368}.doc-header .meta-item{display:flex;align-items:center;gap:6px}.doc-header .meta-item strong{color:#1d1d1f}h2{font-family:'Google Sans',sans-serif;font-size:22px;color:#1a73e8;margin:40px 0 16px;padding-bottom:8px;border-bottom:1px solid #e8eaed}h3{font-family:'Google Sans',sans-serif;font-size:17px;color:#202124;margin:28px 0 12px}p{margin-bottom:14px}ul,ol{margin:0 0 18px 24px}li{margin-bottom:8px}table{width:100%;border-collapse:collapse;margin:16px 0 24px;font-size:13px}th,td{padding:10px 14px;text-align:left;border:1px solid #dadce0}th{background:#e8f0fe;font-weight:600;color:#1565c0}td{color:#3c4043}tr:nth-child(even) td{background:#fafafa}code{background:#f1f3f4;padding:2px 8px;border-radius:4px;font-size:13px}.signature-section{margin-top:64px;page-break-inside:avoid}.signature-section .section-title{font-family:'Google Sans',sans-serif;font-size:18px;font-weight:700;color:#1d1d1f;margin-bottom:24px;padding-bottom:12px;border-bottom:2px solid #1d1d1f}.signature-grid{display:grid;grid-template-columns:1fr 1fr;gap:48px}.signature-block{border:1px solid #dadce0;border-radius:12px;padding:32px;background:#fafafa}.signature-block .role{font-family:'Google Sans',sans-serif;font-size:16px;font-weight:700;margin-bottom:4px}.signature-block .name{font-size:14px;color:#5f6368;margin-bottom:24px}.signature-line{border-bottom:1px solid #1d1d1f;height:48px;margin-bottom:8px}.signature-label{font-size:12px;color:#80868b;margin-bottom:16px}.stamp-area{border:2px dashed #dadce0;border-radius:8px;height:100px;display:flex;align-items:center;justify-content:center;color:#80868b;font-size:12px;margin-top:16px}.doc-footer{margin-top:48px;padding-top:24px;border-top:2px solid #e8eaed;font-size:12px;color:#5f6368;text-align:center}.doc-footer p{margin-bottom:4px}@media print{body{max-width:100%;padding:20px;font-size:12px}.signature-section{page-break-before:always}}</style>
</head>
<body>

<div class="doc-id-bar"><span class="doc-id">SKL-CT-005</span><span>Skolyn Platform Documentation</span><span class="doc-class">CONFIDENTIAL</span></div>

<div class="doc-header">
  <h1>Pulmonary Nodule Management</h1>
  <div class="subtitle">AI-Powered Nodule Detection, Volumetric Measurement, Malignancy Risk Stratification, and Lung-RADS Follow-Up Tracking</div>
  <div class="meta-grid">
    <div class="meta-item"><strong>Version:</strong> 3.0</div>
    <div class="meta-item"><strong>Last Updated:</strong> February 2026</div>
    <div class="meta-item"><strong>Classification:</strong> Confidential</div>
    <div class="meta-item"><strong>Owner:</strong> CT Engineering</div>
  </div>
</div>

<h2>1. Overview</h2>
<p>Pulmonary nodule management is one of the most critical clinical applications of chest CT AI. Lung cancer is the leading cause of cancer-related mortality worldwide, with 5-year survival rates dramatically influenced by stage at diagnosis: &gt;70% for Stage IA versus &lt;10% for Stage IV. Low-dose CT (LDCT) screening reduces lung cancer mortality by 20-24% (NLST, NELSON trials), but generates substantial follow-up burden — approximately 25-30% of LDCT screening examinations identify at least one pulmonary nodule requiring characterization and management. Skolyn's pulmonary nodule management within Terbium OS provides automated nodule detection, 3D segmentation and volumetric measurement, malignancy risk stratification, Lung-RADS classification, and longitudinal tracking across serial examinations with automated growth rate calculation.</p>

<h2>2. Nodule Detection</h2>
<p>The nodule detection engine uses a cascaded 3D object detection architecture operating on full-resolution thin-slice CT data (typically 0.5-1.25mm slice thickness). The first stage uses a 3D Region Proposal Network (RPN) on downsampled volumes to identify candidate nodule locations at high sensitivity with moderate specificity. The second stage applies a high-resolution 3D classification network (ResNet-3D-50) to each candidate location for false positive reduction, classifying each candidate as true nodule versus mimicker (vessel cross-section, lymph node, mucus plug, artifact). The detection engine identifies nodules as small as 3mm in diameter with 96.4% sensitivity at 1 false positive per scan on the LUNA16 benchmark. The system handles all nodule types: solid, part-solid (including ground-glass component measurement), and pure ground-glass nodules, with type-specific characterization pipelines.</p>

<h2>3. Volumetric Measurement</h2>
<p>Automated 3D segmentation provides volumetric nodule measurement, which is more accurate and reproducible than 2D diameter measurement for assessing nodule growth. The segmentation network (3D U-Net with attention gates) delineates the nodule boundary on every CT slice, producing a 3D surface mesh from which volume and effective diameter are computed. For part-solid nodules, the solid component is segmented and measured independently from the ground-glass component, as the solid component volume is the primary determinant of malignancy risk. Volume doubling time (VDT) is automatically calculated when prior CT data is available, using affine registration to align current and prior studies and matching corresponding nodules across time points.</p>

<h2>4. Lung-RADS Classification</h2>
<table>
  <tr><th>Category</th><th>Criteria</th><th>Recommendation</th><th>Cancer Probability</th></tr>
  <tr><td>1 - Negative</td><td>No nodules / benign (calcified, fat)</td><td>Annual LDCT</td><td>&lt;1%</td></tr>
  <tr><td>2 - Benign</td><td>Solid &lt;6mm, GGN &lt;30mm</td><td>Annual LDCT</td><td>&lt;1%</td></tr>
  <tr><td>3 - Probably Benign</td><td>Solid 6-8mm, GGN &gt;/=30mm</td><td>6-month LDCT</td><td>1-2%</td></tr>
  <tr><td>4A - Suspicious</td><td>Solid 8-15mm, new GGN &lt;20mm w/ solid</td><td>3-month LDCT or PET/CT</td><td>5-15%</td></tr>
  <tr><td>4B - Very Suspicious</td><td>Solid &gt;/=15mm, growing part-solid</td><td>Tissue sampling or PET/CT</td><td>&gt;15%</td></tr>
  <tr><td>4X - High Suspicion</td><td>4A/4B + additional suspicious features</td><td>Tissue sampling</td><td>&gt;30%</td></tr>
</table>

<h2>5. Malignancy Risk Model</h2>
<p>Beyond Lung-RADS classification, Skolyn provides a continuous malignancy probability estimate using a multi-feature model incorporating nodule size (volume), morphology (shape, margin characteristics — spiculation, lobulation), density (mean and heterogeneity within the nodule), location (upper lobe nodules higher risk), patient demographics (age, sex), smoking history (pack-years), and growth rate (VDT from prior studies when available). The malignancy risk model is calibrated against biopsy-confirmed outcomes, achieving AUC of 0.94 for malignancy prediction on a validation cohort of 3,200 nodules with pathological ground truth.</p>

<h2>6. Longitudinal Tracking</h2>
<p>The longitudinal tracking database maintains a per-patient nodule inventory across all CT studies, automatically matching nodules between scans and computing interval changes. A patient timeline visualization shows each nodule's volume trajectory with growth trend lines and VDT calculation. Automated follow-up reminders are generated based on Lung-RADS recommendations, integrating with the EHR to create orders for follow-up imaging at appropriate intervals. The system flags overdue follow-up examinations, reducing the risk of lost-to-follow-up — a significant clinical problem where actionable nodules go untracked, potentially delaying lung cancer diagnosis.</p>

<h2>7. Document Revision History</h2>
<table>
  <tr><th>Version</th><th>Date</th><th>Author</th><th>Changes</th></tr>
  <tr><td>1.0</td><td>2024-06-15</td><td>CT Engineering</td><td>Initial release</td></tr>
  <tr><td>2.0</td><td>2025-06-01</td><td>CT Engineering</td><td>Added volumetrics, Lung-RADS v1.1</td></tr>
  <tr><td>3.0</td><td>2026-02-10</td><td>CT Engineering</td><td>Updated risk model, LUNA16 results</td></tr>
</table>

<div class="signature-section">
  <div class="section-title">Authorization & Approval</div>
  <p style="font-size:13px;color:#5f6368;margin-bottom:24px;">This document has been reviewed and approved by the undersigned officers of Skolyn.</p>
  <div class="signature-grid">
    <div class="signature-block"><div class="role">Chief Technology Officer (CTO)</div><div class="name">Skolyn Technology Division</div><div class="signature-line"></div><div class="signature-label">Signature</div><div style="display:flex;justify-content:space-between;margin-bottom:16px"><div><span class="signature-label">Printed Name:</span> ___________________________</div></div><div><span class="signature-label">Date:</span> ______ / ______ / ____________</div><div class="stamp-area">Official Stamp / Seal</div></div>
    <div class="signature-block"><div class="role">Chief Executive Officer (CEO)</div><div class="name">Skolyn Executive Office</div><div class="signature-line"></div><div class="signature-label">Signature</div><div style="display:flex;justify-content:space-between;margin-bottom:16px"><div><span class="signature-label">Printed Name:</span> ___________________________</div></div><div><span class="signature-label">Date:</span> ______ / ______ / ____________</div><div class="stamp-area">Official Stamp / Seal</div></div>
  </div>
</div>

<div class="doc-footer"><p><strong>Skolyn</strong> — Redefining Medical Imaging Through Explainable AI</p><p>Document ID: SKL-CT-005 | Version 3.0 | Classification: Confidential</p><p>&copy; 2026 Skolyn. All rights reserved.</p></div>

</body>
</html>
